Insmed Inc (INSM)vsNautilus Biotechnology Inc (NAUT)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
NAUT
Nautilus Biotechnology Inc
$3.91
-1.01%
HEALTHCARE · Cap: $383.49M
Smart Verdict
WallStSmart Research — data-driven comparison
NAUT leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
NAUT
Avoid25
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Conservative balance sheet, low leverage
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Grey zone — moderate risk
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : NAUT
The strongest argument for NAUT centers on Debt/Equity.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : NAUT
The primary concerns for NAUT are Revenue Growth, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while NAUT is a value play — different risk/reward profiles.
NAUT carries more volatility with a beta of 1.36 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
NAUT generates stronger free cash flow (-13M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 25/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Nautilus Biotechnology Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Nautilus Biotechnology, Inc., a development-stage life sciences company, is dedicated to creating platform technology to quantify and unlock proteome complexity. The company is headquartered in Seattle, Washington.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?